Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

ADMINISTRATION of LMP-SPECIFIC CYTOTOXIC T-LYMPHOCYTES to PATIENTS with RELAPSED EBV-POSITIVE LYMPHOMA

NCT01956084 is registered in ClinicalTrials.gov with Catherine Bollard as lead sponsor.

NCT NCT01956084
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01956084 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
ADMINISTRATION of LMP-SPECIFIC CYTOTOXIC T-LYMPHOCYTES to PATIENTS with RELAPSED EBV-POSITIVE LYMPHOMA
Lead sponsor
Catherine Bollard
Phase
Phase 1
Overall status
Completed
Start date
November 30, 2013
Completion date
October 15, 2019
Enrollment
10 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hodgkin disease, leiomyosarcoma, lymphoepithelioma, non hodgkin lymphoma, severe chronic active ebv infection syndrome (scaebv)